Updated results of bladder-sparing trimodality approach for invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 4, 2010, Pages 368-374

  Zapatero, Almudena ^a   Martin de Vidales, Carmen ^a   Arellano, Ramón ^a   Bocardo, Gloria ^a   Pérez, Mar ^a   Ríos, Patricia ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Bladder cancer; Bladder preservation; Cisplatin; Hyperfractionated radiotherapy; Radiochemotherapy

Indexed keywords

CISPLATIN; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; SALVAGE THERAPY; STATISTICAL SIGNIFICANCE; TRANSURETHRAL RESECTION; TREATMENT FAILURE; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 77953870387     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.01.031     Document Type: Article

References (24)

1. Sweeney C., Bajorin D.F., and Sternberg C. Muscle-invasive bladder cancer: What have we learned and what's new on the horizon?. J Clin Oncol 8 (2008) 200-208
2. Rödel C., Weiss C., and Sauer R. Organ preservation by combined modality treatment in bladder cancer: The European perspective. Semin Radiat Oncol 15 (2004) 28-35
3. Coen J.J., Zietman A.L., Kaufman D.S., et al. Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer. Urol Oncol 25 (2007) 76-84
4. Fernando S.A., and Sandler H.M. Multimodality bladder preservation therapy for muscle-invasive bladder tumors. Semin Oncol 34 (2007) 129-134
5. Chung P.W.M., Bristow R.G., Milosevic M.F., et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 25 (2007) 303-309
6. Zapatero A., Martin de Vidales C., and Marin A. Invasive bladder cancer: A single-institution experience with bladder-sparing approach. Int J Cancer Radiat Oncol Invest 90 (2000) 287-294
7. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radat Oncol Biol Phys 31 (1995) 1341-1346
8. Cox D.R. Regression models and life tables. J R Stat Soc B 34 (1972) 187-220
9. Weiss C., Engehausen D.G., Krause F.S., et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68 (2007) 1072-1080
10. Zietman A.L., Sacco D., Skowronski U., et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 170 (2003) 1772-1776
11. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20 (2002) 3061-3071
12. Hagan M.P., Winter K.A., Kaufman D.S., et al. RTOG 97-06; initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 665-672
13. Milosevic M., Gospodarowicz M., Zietman A., et al. Radiotherapy for bladder cancer. Urology 69 Suppl 1A (2007) 80-92
14. Ghersi D., Stewart L.A., Parmar M.K.B., et al. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomized controlled trial. Lancet 354 (1999) 533-540
15. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 361 (2003) 1927-1934
16. Nichols Jr. R.C., Sweetser M.G., Mahmood S.K., et al. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: A well-tolerated combination. Int J Cancer 90 (2000) 281-286
17. Sangar V.K., McBain C.A., Lyons J., et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 61 (2005) 420-425
18. Dunst J., Weigel C., Heynemann H., et al. Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlenther Onkol 175 Suppl. 3 (1999) 7-10
19. Majewski W., Maciejewski B., Majewski S., et al. Clinical radiobiology of stage T2-T3 bladder cancer. Int J Radiat Oncol Biol Phys 60 (2004) 60-70
20. Horwich A., Dearnaley D., Huddart R., et al. A randomized trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol 75 (2005) 34-43
21. Poortmans P.M., Richaud P., Collette L., et al., EORTC Radiation Oncology Group. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder. Acta Oncol 47 5 (2008) 937-940
22. Cowan R.A., McBain C.A., Ryder W.D., et al. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 197-207
23. Chakravarti A., Winter K., Wu C.L., et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62 (2005) 309-317
24. Pollack A., Wu C.S., Czerniak B., et al. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 3 (1997) 1823-1829